Slaven Erceg Vukicevic

TEAM LEADER
Advanced Therapies
Centro de Investigacion Principe Felipe
Spain

Academician Molecular Biology
Biography

Dr. Erceg has more than six years of postdoctoral experience dedicated to cell therapy involving human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), as a therapeutic tool for treatment of neurodegenerative diseases. He developed an improved protocol for differentiation of hESCs and iPSCs toward neural progenitors, oligodendrocytes and motoneurons, for the treatment of rat model of spinal cord injury (Erceg et al., 2008, Erceg et al., 2010a), and cerebellar neuronal progenitors for the treatment of animal cerebellar ataxia models (Erceg et al., 2010b, Erceg et al., 2011). Recently he has extended his interest to rare retinal diseases and is currently developing a study on the therapeutic potential of pluripotent cells in retinal degenerative disease involving gene correction In total he produced 40 papers as main and co-author in high ranking journals like Stem Cells, Stem Cells and Development, Neuroscience, Hepathology etc

Research Intrest

Stem Cell Therapies in Neurodegenerative Diseases, Another subject of interest is hereditary retinal dystrophies. 

List of Publications
Transplanted oligodendrocytes and motoneuron progenitors generated from human embryonic stem cells promote locomotor recovery after spinal cord transection.
Concise review: human pluripotent stem cells in the treatment of spinal cord injury.
Brief report: astrogliosis promotes functional recovery of completely transected spinal cord following transplantation of hESC-derived oligodendrocyte and motoneuron progenitors.
Human iPSC derived disease model of MERTK-associated retinitis pigmentosa.